nafamostat has been researched along with Anemia, Hemolytic, Autoimmune in 2 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Anemia, Hemolytic, Autoimmune: Acquired hemolytic anemia due to the presence of AUTOANTIBODIES which agglutinate or lyse the patient's own RED BLOOD CELLS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamamura, M | 1 |
| Miyamoto, T | 1 |
| Yao, H | 1 |
| Ijichi, S | 1 |
| Sano, Y | 1 |
| Une, F | 1 |
| Maruyama, I | 1 |
| Osame, M | 1 |
2 other studies available for nafamostat and Anemia, Hemolytic, Autoimmune
| Article | Year |
|---|---|
Open heart surgery in a patient with autoimmune hemolytic anemia.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Anti-Inflammatory Agents; Benzamidines; Betamethasone; Cardiopu | 1999 |
[Accessory use of protease-inhibiting agents for disease remission in a patient with autoimmune hemolytic anemia associated with B-CLL].
Topics: Aged; Anemia, Hemolytic, Autoimmune; Benzamidines; Complement Activation; Complement Inactivator Pro | 1990 |